434 related articles for article (PubMed ID: 26303130)
1. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.
Tapper EB; Hunink MG; Afdhal NH; Lai M; Sengupta N
PLoS One; 2016; 11(2):e0147237. PubMed ID: 26905872
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
Sangha K; Chang ST; Cheung R; Deshpande VS
Hepatology; 2023 May; 77(5):1702-1711. PubMed ID: 37018145
[TBL] [Abstract][Full Text] [Related]
4. The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease.
Tapper EB; Challies T; Nasser I; Afdhal NH; Lai M
Am J Gastroenterol; 2016 May; 111(5):677-84. PubMed ID: 26977758
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease.
Dincses E; Yilmaz Y
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1149-53. PubMed ID: 26049712
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System.
Vilar-Gomez E; Lou Z; Kong N; Vuppalanchi R; Imperiale TF; Chalasani N
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2305-2314.e12. PubMed ID: 32289535
[TBL] [Abstract][Full Text] [Related]
7. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of nonalcoholic steatohepatitis screening.
Zhang E; Wartelle-Bladou C; Lepanto L; Lachaine J; Cloutier G; Tang A
Eur Radiol; 2015 Nov; 25(11):3282-94. PubMed ID: 25994191
[TBL] [Abstract][Full Text] [Related]
10. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting.
Congly SE; Shaheen AA; Swain MG
PLoS One; 2021; 16(5):e0251741. PubMed ID: 34019560
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
[TBL] [Abstract][Full Text] [Related]
13. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
[TBL] [Abstract][Full Text] [Related]
14. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
[TBL] [Abstract][Full Text] [Related]
15. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.
Chan WK; Nik Mustapha NR; Mahadeva S
Hepatol Int; 2015 Oct; 9(4):594-602. PubMed ID: 25788185
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
Mózes FE; Lee JA; Selvaraj EA; Jayaswal ANA; Trauner M; Boursier J; Fournier C; Staufer K; Stauber RE; Bugianesi E; Younes R; Gaia S; Lupșor-Platon M; Petta S; Shima T; Okanoue T; Mahadeva S; Chan WK; Eddowes PJ; Hirschfield GM; Newsome PN; Wong VW; de Ledinghen V; Fan J; Shen F; Cobbold JF; Sumida Y; Okajima A; Schattenberg JM; Labenz C; Kim W; Lee MS; Wiegand J; Karlas T; Yılmaz Y; Aithal GP; Palaniyappan N; Cassinotto C; Aggarwal S; Garg H; Ooi GJ; Nakajima A; Yoneda M; Ziol M; Barget N; Geier A; Tuthill T; Brosnan MJ; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
Gut; 2022 May; 71(5):1006-1019. PubMed ID: 34001645
[TBL] [Abstract][Full Text] [Related]
17. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
[TBL] [Abstract][Full Text] [Related]
18. Clinical Performance of Transient Elastography With Comparison to Quantitative Magnetic Resonance Imaging, Ultrasound, and Biopsy in Children and Adolescents With Known or Suspected Fatty Liver Disease.
P V Alves V; T Trout A; Dewit M; Mouzaki M; Arce-Clachar AC; S Bramlage K; R Dillman J; A Xanthakos S
Child Obes; 2023 Oct; 19(7):461-469. PubMed ID: 36269577
[No Abstract] [Full Text] [Related]
19. Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis.
Choo BP; Goh GBB; Chia SY; Oh HC; Tan NC; Tan JYL; Ang TL; Bee YM; Wong YJ
Ann Acad Med Singap; 2022 Nov; 51(11):686-694. PubMed ID: 36453216
[TBL] [Abstract][Full Text] [Related]
20. Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis.
Tapper EB; Afdhal NH
Curr Opin Gastroenterol; 2015 May; 31(3):192-8. PubMed ID: 25730177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
